GLP-1 prescribing in 8 to 11 year olds went up 310-fold, and not evenly

Design

retrospective cross-sectional study of repeated annual cohorts from a large US electronic health record network, binomial logistic regression

Population

3,520,531 children aged 8–11 with obesity and without diabetes, January 2019 to June 2026

Primary outcome

proportion prescribed a GLP-1 receptor agonist and trend over time

Effect

0.03% in 2019 to 9.3% in 2026 (p<0.001), 0.6% overall; comorbidity 188.9/10,000; low vs high social vulnerability 76.1 vs 49.2/10,000

Paediatric obesity guidelines permit consideration of GLP-1 receptor agonists from age 8 upwards, and no one had documented what prescribers actually did with that permission. This cross-sectional study pulled repeated annual cohorts from Epic Cosmos: 3,520,531 US children aged 8 to 11 with obesity and without diabetes, from January 2019 to June 2026.

Prevalent prescribing rose from 0.03% in 2019 to 9.3% in 2026 — a 310-fold increase — while remaining uncommon at 0.6% across the whole period. The distribution is where the interest lies. Prescribing was higher in 11-year-olds than 8-year-olds (79.5 versus 41.5 per 10,000), higher in girls than boys (75.9 versus 42.8), and much higher in children with obesity-related comorbidity (188.9 per 10,000).

Those first three patterns look like appropriate clinical targeting: older children, greater cardiometabolic risk. The fourth does not. Children with low social vulnerability were prescribed at 76.1 per 10,000 against 49.2 for those with high social vulnerability — the inverse of where paediatric obesity and its complications concentrate. Whatever is driving that gap, it is not clinical need.

• The sex difference — girls prescribed at nearly twice the rate of boys — is not explained by obesity prevalence or complication rates and deserves examination in your own practice.
• These drugs are not licensed for this age group in India and there is no paediatric evidence base here; the relevance is the prescribing pattern, not the product.
• Comorbidity-driven prescribing is defensible; take the time to document which comorbidity justified it.
• Growth, puberty, nutritional adequacy and eating-disorder screening all need monitoring on these drugs in a growing child, and none of that is captured in a prescription record.
• Behavioural and family-based intervention remains the foundation and was not measured here.

Why it matters

The drug is reaching children with less social vulnerability more often than those with more, which is the opposite of where the disease burden sits.

Don't overread it

This describes prescribing patterns in a US record network; it says nothing about whether the drugs helped these children.

The statistics, in plain English

A 310-fold increase sounds enormous and is: it is the ratio of 9.3% to 0.03%, from a base so small that any uptake produces a dramatic multiple. The absolute figure — 0.6% of children over the whole period — is the one that describes practice. Note also that this is prescribing recorded in one large US electronic record network, which captures the prescription written rather than the drug dispensed, taken or continued.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.